
Misonix, Inc. MSON
Misonix, Inc. Financial Ratios 2011-2026 | MSON
Annual Financial Ratios Misonix, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-10.6 | -30.6 | -19.9 | -41.2 | -40.5 | 12.5 | 34.9 | -13.6 | 47.4 | -4.8 |
P/S |
3.0 | 5.8 | 4.1 | 2.5 | 2.1 | 3.1 | 2.8 | 2.4 | 1.1 | 1.2 |
EV/EBITDA |
-12.0 | -38.0 | -93.0 | -10.4 | -9.2 | -218.9 | -26.5 | -6.7 | -14.3 | -3.9 |
PEG |
0.21 | -4.33 | 0.06 | 1.24 | 0.34 | 0.04 | 0.23 | 0.02 | 0.43 | 0.22 |
P/B |
1.3 | 10.4 | 6.2 | 2.5 | 1.9 | 2.9 | 3.0 | 2.6 | 1.1 | 1.1 |
P/CF |
-6.8 | -49.9 | -137.4 | -34.9 | -51.5 | 36.0 | 97.5 | -33.4 | -8.4 | -5.6 |
ROE % |
-11.88 | -34.03 | -31.20 | -5.97 | -4.80 | 23.45 | 8.52 | -19.39 | 2.35 | -23.76 |
ROA % |
-8.55 | -24.66 | -26.23 | -5.04 | -4.23 | 21.06 | 7.13 | -15.39 | 2.00 | -19.25 |
ROCE % |
-10.40 | -33.52 | -12.05 | -23.44 | -23.85 | -7.21 | -15.52 | -38.34 | -9.47 | -20.20 |
DSO |
64.6 | 50.4 | 52.2 | 68.7 | 61.1 | 73.7 | 80.4 | 73.2 | 78.1 | 63.3 |
DIO |
272.4 | 232.0 | 187.1 | 221.8 | 279.2 | 215.7 | 259.4 | 198.3 | 247.3 | 201.2 |
DPO |
83.1 | 169.0 | 66.9 | 82.7 | 67.3 | 57.5 | 101.5 | 108.6 | 85.1 | 71.2 |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Misonix, Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Alphatec Holdings
ATEC
|
$ 11.24 | 3.12 % | $ 1.69 B | ||
|
Cytosorbents Corporation
CTSO
|
$ 0.59 | -2.87 % | $ 36.7 M | ||
|
EDAP TMS S.A.
EDAP
|
$ 3.38 | 2.42 % | $ 127 M | ||
|
AxoGen
AXGN
|
$ 33.02 | 3.32 % | $ 1.52 B | ||
|
Helius Medical Technologies
HSDT
|
$ 1.95 | 3.17 % | $ 1.19 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Align Technology
ALGN
|
$ 179.33 | 3.58 % | $ 13.4 B | ||
|
AdaptHealth Corp.
AHCO
|
$ 12.23 | 0.49 % | $ 1.65 B | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M | ||
|
IRIDEX Corporation
IRIX
|
$ 1.01 | 1.51 % | $ 17.1 M | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
$ 287.55 | 3.02 % | $ 8.11 B | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
$ 39.05 | 3.88 % | $ 5.82 K | ||
|
LivaNova PLC
LIVN
|
$ 64.43 | 2.62 % | $ 3.51 B | ||
|
LENSAR
LNSR
|
$ 5.75 | 0.84 % | $ 68.8 M | ||
|
Boston Scientific Corporation
BSX
|
$ 62.92 | 1.83 % | $ 93.1 B | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
$ 9.95 | 14.57 % | $ 282 M | ||
|
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
$ 24.44 | 1.33 % | $ 207 M | ||
|
CryoLife, Inc.
CRY
|
- | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | ||
|
Inogen
INGN
|
$ 6.47 | 2.21 % | $ 172 M | ||
|
CHF Solutions, Inc.
CHFS
|
- | 1.15 % | $ 34.5 M | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
- | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
- | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
- | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
- | 0.03 % | $ 1.58 B | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
$ 16.82 | 5.32 % | $ 395 M | ||
|
Globus Medical
GMED
|
$ 92.99 | 2.84 % | $ 12.6 B | ||
|
Butterfly Network
BFLY
|
$ 4.23 | 2.92 % | $ 895 M | ||
|
Intersect ENT, Inc.
XENT
|
- | - | $ 955 M | ||
|
Stryker Corporation
SYK
|
$ 345.77 | 1.95 % | $ 132 B | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
TELA Bio
TELA
|
$ 0.55 | -3.07 % | $ 25.8 M | ||
|
Delcath Systems
DCTH
|
$ 10.42 | 3.78 % | $ 373 M | ||
|
Myomo
MYO
|
$ 0.71 | 3.41 % | $ 29.7 M | ||
|
Inspire Medical Systems
INSP
|
$ 55.32 | 2.41 % | $ 1.62 B | ||
|
TransMedics Group
TMDX
|
$ 112.92 | -0.95 % | $ 3.84 B | ||
|
CONMED Corporation
CNMD
|
$ 38.1 | 3.7 % | $ 1.18 B |